Navigation Links
OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
Date:6/4/2013

STOCKHOLM, June 4, 2013 /PRNewswire/ --

OxThera AB has been granted three Japanese patents during 2012 and 2013. The patents will secure the pharmaceutical composition and the method for treating and preventing oxalate-related disease with micro-organisms and enzymes and will further strengthen the Company's patent estate for this unmet medical need.

"We are continuously working to further strengthen the world-wide rights for our lead product Oxabact®" for treatment of Primary Hyperoxaluria, an orphan disease," says Elisabeth Lindner , CEO of OxThera. "The Japanese rights are important additions to our already granted patents in the EU and the US. Japan is an important market for hyperoxaluria" Elisabeth Lindner continues.

OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in seven patent families with approximately eighty applications filed. The new granted Japanese patents have numbers 4996780, 5047190 and 5203217.

Oxabact® is an oral product composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), administered in capsules. The drug is designed for delivery in the lower part of the small intestine, where enteric elimination of endogenous oxalate is initiated. OxThera is currently pursuing a complete Oxabact® clinical development plan in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria.

About Primary Hyperoxaluria

Primary Hyperoxaluria is a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including kidney stone formation and/or calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. There is a high medical need for effective treatments of Primary Hyperoxaluria. Currently, the only available cure is a combined liver and kidney transplantation.

Oxabact® holds orphan drug designations in the EU and the US for the treatment of Primary Hyperoxaluria.

About OxThera

OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for the prevention of oxalate malabsorption and recurring kidney stones in Secondary Hyperoxaluria. OxThera operates through the head office in Stockholm, Sweden, and its subsidiary OxThera Inc. in Alachua, Florida, USA.

For further information, please contact Elisabeth Lindner , CEO of OxThera AB, Phone +46-8-660-02-23


http://www.oxthera.com


'/>"/>
SOURCE OxThera
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor
2. Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals
3. RxAlly Strengthens Leadership Team With New Chief Information Officer Mike Groh
4. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
5. Actinium Pharmaceuticals Strengthens Management Team
6. Pharmalink AB Strengthens Senior Management Team
7. Jardogs Strengthens Leadership Team with the Addition of Two Seasoned Healthcare Executives
8. inVentiv Health Strengthens Clinical Leadership Team
9. Alliqua Strengthens and Realigns Executive Team
10. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
11. TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Vivify Health, the pioneer ... has been awarded a very significant patent for the ... to continual care via digital health.  This landmark patent ... property and further secures Vivify,s position as the leader ... 2009, was the first company to apply consumer mobile ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... prescription opioid overdose deaths now claim the lives of 62 Americans each day.(1) ... filings against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... designed to recognize elevated anxiety levels in people with addiction who are served ... Smart Patch, a biosensing wearable device that monitors heart and breath rates to ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... health of individuals with HIV because it is not known to have significant ... have favorable effects to both lower cholesterol levels and dampen inflammation in the ...
(Date:4/24/2017)... ... ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at the ... 2-day program. , An attendee at a recent PAINWeekEnd said, "Very helpful, wish ... course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by Dr. ...
(Date:4/24/2017)... FOREST KNOLLS, Calif. (PRWEB) , ... April 24, 2017 , ... ... and health topics, but she has not found any of them to be very ... weekly actions to slowly and easily make changes in their health. It prompted her ...
Breaking Medicine News(10 mins):